Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
Read More Chemical Industry News Croda International reports 8% Q1 2025 sales growth, reaffirms FY guidance Croda International's Q1 2025 sales surged 8%, propelling a 10.7% stock rally. Discover the factors driving this growth and what it means for investors. byPallavi MadhirajuApril 23, 2025